Senior Accountant
Vaxcyte
Senior Accountant
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
Summary:
Reporting to the Associate Director, Accounting, the Senior Accountant leads key month-end close activities — including journal entries, account reconciliations, prepaid amortization schedules, financial statement fluctuation analyses, audit support, and ad hoc projects — and partners closely with cross-functional teams across a fast-growing, clinical-stage biotech.
The ideal candidate learns quickly, including in uncharted territory, and is comfortable operating in a fast-paced environment. This person is flexible, detail-oriented, and brings a genuine passion for process improvement and innovation, paired with strong oral and written communication skills.
Essential Functions:
Requirements:
Skills & Attributes:
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte